Currently, there is significant interest in tailoring therapy for patients with HER2-positive breast cancer by decreasing cytotoxic chemotherapy, as about a third of patients may achieve an excellent outcome with HER2-directed treatment alone without the addition of chemotherapy [7]. Here, ERBB2 is linked to breast carcinoma.